% | $
Quotes you view appear here for quick access.

MannKind Corp. Message Board

  • kevinmik kevinmik Jul 5, 2013 11:43 AM Flag

    How About A Phase 3 Press Release That Also Includes A Signed Partnership Deal ?

    This is just my opinion and if you feel its repetitive just ignore it.... Mannkind already has Phase 3 results and they know both trials meet or exceed expectation. Having Phase 3 results in hand, Mannkind next secured financial arrangement with Deerfield to strengthen their negotiating position prior to restarting partnership talks. Having both Phase 3 results and Deerfield Agreement, Mannkind is now in negotiations to finalize a partnership deal. Next press release could be even better than what's expected to happen and will include not only Phase 3 results, but a signed global partnership deal. Mannkind and new Partner will move forward with powerful Phase 3 results and file an NDA re-submission. I think Mannkind and their new Partner are confidant about FDA approval based on Phase 3 results. JMO

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • It is likely that no one wants Al Mann for a partner. This business is built to be sold and bolted on to an existing marketing organization . It might fetch $15 after FDA approval.

      But it is doubtful that any big Pharma will partner with the serial liar Al Mann.

    • Kevinmik = Itell = Pumping TOOL.

    • First thing, if they know the trial results, the mgmt has to disclose it as this material information. Second they cannot disclose that information only to a select investor.
      If the numbers are known, why negotiate such a one-sided deal with Deerfield? Substitute 3.75% debt with 9.75 debt? Shouldn't they wait for a better deal after a month. I think the mgmt is hedging
      Matt and Palumbo are selling. Go back to 2010 FDA rejection and see what happened days, weeks before that.

    • The data is available to potential partners as soon as MNKD wants it to be after the lock. Anything is possible.

    • What are you smoking?

      • 2 Replies to killer888000
      • Wow I expected a short to attack my post, but you were really quick. How many of you are assigned to monitor this board to attack anything positive being said about Mannkind? It's not working...

      • Pfeffer Matthew J who is Corporate VP and CFO at MANNKIND CORP sold 10,000 shares at $7.00 per share for a total value of $70,000.00 on July 2, 2013. Following this transaction, the Corporate VP and CFO owned 83,654 shares meaning that the stake was reduced by 10.68% with the 10,000 share sell-off.

        The shares most recently traded at $6.93, up $0.06, or 0.87% since the insider transaction. Historical insider transactions for MannKind Corporation go as follows:

        4-Week # shares bought: 9,058
        4-Week # shares sold: 10,000
        12-Week # shares bought: 9,058
        12-Week # shares sold: 36,829
        24-Week # shares bought: 9,058
        24-Week # shares sold: 36,829
        The average volume for MannKind Corporation has been 8.1 million shares per day over the past 30 days. MannKind Corporation has a market cap of $2.1 billion and is part of the health care sector and drugs industry. Shares are up 212.99% year to date as of the close of trading on Wednesday.

0.4901-0.0049(-1.00%)Oct 27 4:00 PMEDT